Sanofi Investors Win Class Cert. In Obesity Drug Suit

Law360, New York (March 20, 2013, 10:06 PM EDT) -- A New York federal judge on Wednesday certified a class of Sanofi-Aventis SA investors who claim the French pharmaceutical giant withheld information about anti-obesity drug Zimulti's link to severe psychiatric problems, finding the lead plaintiffs' securities fraud claims were typical of the class as a whole.

U.S. District Judge George B. Daniels rejected Sanofi's argument that the claims did not meet the typicality requirement for class actions because the lead plaintiffs' asset managers were closely following financial markets and the financial press at the time the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re: sanofi-aventis Securities Litigation


Case Number

1:07-cv-10279

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

George B. Daniels

Date Filed

November 13, 2007

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.